Last edition
News about
OXB Signs Multi-Year Commercial Supply Deal with Bristol Myers Squibb
Oxford Biomedica will serve as the commercial manufacturer of lentiviral vectors for Bristol Myers Squibb’s CAR-T programmes under a new multi-year supply agreement, which includes a five-year initial term with an option to extend.
Patent Expiry Headwinds to Drive Novartis Operating Profit Down in 2026
Swiss pharmaceutical major Novartis has forecast a modest decline in operating profit for 2026, marking its first annual drop in a decade amid the looming impact of key drug patent expiries.
Telangana Cracks Down on Illegal Medical Device Manufacturing in Ranga Reddy
The Drugs Control Administration (DCA) of Telangana has uncovered an unlicensed medical device manufacturing and distribution operation in the Ranga Reddy district, leading to the seizure of products and supporting materials valued at Rs 4 lakh.
Insilico Medicine Receives USD 5 Million from Menarini
Insilico received an additional $5 million milestone from Menarini following first-in-patient dosing in a Phase I trial of MEN2501, a generative AI-designed KIF18A inhibitor for chromosomally unstable solid tumours.
Mankind Pharma Sees Margin Expansion, Chronic Segment Gains in Q3FY26
Mankind Pharma announced its consolidated financial results for the third quarter and nine months ended December 31, 2025, reporting steady growth driven by improved performance in its domestic pharmaceutical business and consolidation of its BSV portfolio.
UK Industry Body Finds Sanofi in Breach Over RSV Therapy Claims Against Pfizer
A UK pharmaceutical industry watchdog has ruled that Sanofi breached the country’s code of practice by making misleading claims about its respiratory syncytial virus (RSV) therapy in comparison with a rival product from Pfizer.
Sanofi Announces Euro 1 Billion Share Buyback Programme for 2026
R&D-driven biopharma major Sanofi to repurchase shares worth up to Euro 1 billion between February and December 2026, reinforcing its capital allocation strategy and long-term growth outlook.
WHO, WTO and WCO Update Global Customs Codes to Fast-Track Vaccine Shipments by 2028
New customs codes under HS 2028 aim to improve global tracking and faster clearance of vaccines and essential medical supplies during health emergencies.
The FDA has granted Priority Review to Datroway for first-line treatment of metastatic triple-negative breast cancer patients ineligible for immunotherapy, with a regulatory decision expected in Q2 2026.
Pfizer's Monthly Injectable GLP-1 Shows Sustained Weight Loss
Pfizer’s phase-II (b) VESPER-III study demonstrated that its ultra-long-acting injectable GLP-1 receptor agonist PF-08653944 delivered statistically significant and sustained weight loss with monthly dosing, supporting its advancement into an expansive phase-III obesity programme planned for 2026.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy